Psilocybin brain scan study aims to unlock new treatments
NCT ID NCT07050368
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial tested multiple doses of MLS101, a low-dose psilocybin capsule, in 20 healthy volunteers. Researchers used brain scans (fMRI) to see how the drug affects brain activity, while also checking safety and how the body processes the drug. The goal is to gather information that could support future treatments for neurological and psychiatric conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Psilocybin
- What this could lead to
- If successful, this study could help develop low-dose psilocybin as a treatment for neurological and psychiatric conditions.
- What could go wrong
- This is an early-phase trial in only 20 healthy people, so results may not apply to patients. Side effects are possible, and the drug may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hammersmith Medicines Research (HMR)
London, NW10 7EW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?